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To evaluate interstitial lung disease associated with systemic sclerosis (SSc-ILD) and its
changes during treatment by using quantitative analysis (QA) compared to semi-quantita-
tive analysis (semiQA) of chest computed tomography (CT) scans. To assess the prognos-
tic value of QA in predicting functional changes.
Materials and methods
We retrospectively selected 35 consecutive patients with SSc-ILD with complete pulmonary
functional evaluation, Doppler-echocardiography, immunological tests, and chest CT scan
at both baseline and follow-up after immunosuppressive therapy. CT images were analyzed
by two chest radiologists for semiQA and by a computational platform for texture analysis of
ILD patterns (CALIPER) for QA. Concordance between semiQA and QA was tested. Trac-
tion bronchiectasis severity was scored. Analysis of ROC curves was performed.
Results
Seventy CT scans were analyzed and QA failed in 4/70 scans. Thus, the final population
included 31/35 patients (51.3±12.1 years). QA had a weak-to-good concordance with
semiQA (ICC reticular:0.275; ICC ground-glass:0.667) and QA correlated better than
semiQA (r = -0.3 to -0.74 vs r = -0.3 to -0.4) with functional parameters. Both methods corre-
lated with traction bronchiectases score and pulmonary artery diameter at CT. A pulmonary
artery diameter�29mm distinguished patients with lower lung volumes and ILD extent
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greater than 39% (p<0.001). Changes in QA patterns during treatment were not accurate
(AUC: 0.50 to 0.70; p>0.05) in predicting disease progression as assessed by functional
parameters, whereas variation in total lung volume at QA accurately predicted changes in
the composite functional respiratory endpoint with FVC% and DLco% (AUC = 0.74; 95%CI:
0.54 to 0.93; p = 0.03).
Conclusions
Pulmonary QA of CT images can objectively quantify specific patterns of ILD changes dur-
ing treatment in patients with SSc-ILD. Changes in QA patterns do not correlate with func-
tional changes, but variation in total lung volume at QA accurately predicted changes in the
composite functional respiratory endpoint with FVC% and DLco%. Pulmonary artery diame-
ter at CT reflects the interstitial involvement, identifying patients with more severe
prognosis.
Introduction
Systemic sclerosis (SSc) is a connective tissue disease with a variety of clinical presentations,
ranging from involvement restricted to the skin and peripheral angiopathy to rapidly progres-
sive forms affecting internal organs. Lungs are one of the most commonly affected organs,
with both parenchyma and pulmonary vessels involvement [1].
Diffusing capacity of the lung for carbon monoxide (DLco) and forced vital capacity (FVC)
levels have traditionally been used as measures of lung disease severity and reductions in both
parameters have been associated with increased mortality in the interstitial lung disease associ-
ated with SSc (SSc-ILD) [2, 3]. Recently Goh et al. proposed a composite functional end-point
with FVC and DLco for predicting survival in patients with SSc-ILD [3] and a decade ago the
same group proposed a radiological score together with FVC to distinguish “limited” versus
“extensive” disease [4, 5]. This approach is restricted to evaluate patient prognosis and is lim-
ited to a semi-quantitative analysis (semiQA) of chest computed tomography (CT) images,
susceptible to observer bias, inter-reader, and intra-reader variability [6]. These limits repre-
sent a critical obstacle especially when evaluating the response to therapy in daily practice,
which is the real unmet need in the assessment of SSc population [7, 8].
Quantitative analysis (QA) of chest CT images has recently become feasible with the advent
of computational platforms able to perform a fully automated lung texture analysis that can
identify and quantify lung fibrosis [9, 10]. One of the available platforms, called Imbio Lung
Texture Analysis (LTA) (Imbio LLC, Minneapolis, MN), is CE (Conformité Européenne)
mark certified and approved for clinical settings. Imbio LTA identifies and quantifies the lung
CT patterns of ILD (i.e. ground-glass, reticular, honeycombing) based on an anatomo-patho-
logical validation [10]. The objectivity, reproducibility, and the full automatism of this tech-
nique make QA a desirable tool to evaluate lung damage and response to therapy in SSc
patients in clinical trials and eventually in daily clinical practice [11].
Therefore, we aimed to evaluate extent and patterns of SSc-ILD and their changes over time
by using QA on chest CT scans, to assess the concordance of QA and semiQA scores, and to
ascertain whether QA correlates more strongly than semiQA with functional data and vascular
CT parameters. Finally, we aimed to assess the prognostic value of QA in predicting
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This is a retrospective study on human subjects, approved by the local ethics committee
(Comitato Etico Fondazione Policlinico universitario “Agostino Gemelli”- Università Cattolica
del Sacro Cuore). Informed consent was waived for this retrospective evaluation. Thirty-five
patients with SSc-ILD admitted to the Scleroderma Clinic of the study center were selected.
Inclusion criteria were those proposed by the European League Against Rheumatism
(EULAR) and the American College of Rheumatology for the diagnosis of SSc [12] and
patients were classified as “limited” and “diffuse” type according to LeRoy classification [13].
Exclusion criteria were the presence of chronic obstructive pulmonary disease, history of lung
cancer, age less than 18 years old, and long-term oxygen therapy (due to poor performance of
these patients at pulmonary function tests–PFT, often left incomplete, and difficulties in
assessing DLco). The baseline evaluation occurred between October 2012 and October 2014
and patients were followed-up to December 2016.
Disease duration was defined as years since the onset of Raynaud’s phenomenon or the first
non-Raynaud’s phenomenon manifestation. Patients with disease duration since the first non-
Raynaud’s phenomenon manifestation less than 3 years were considered to have an early
disease.
The included patients underwent PFT, Doppler-echocardiography, immunological tests,
and unenhanced chest CT scan before and after therapy. Immunosuppressive therapies were
either rituximab or conventional immunosuppressive drugs (azathioprine, mycophenolate, or
cyclophosphamide).
Pulmonary function tests
Spirometric evaluation with flow-sensing computer-connected spirometers (Biomedin Spi-
rometer) provided data on pulmonary function, in particular measurements of predicted val-
ues of forced vital capacity (FVC%), total lung capacity (TLC%), and residual volume (RV%)
were acquired adopting the American Thoracic Society/European Respiratory Society (ATS/
ERS) standards [14]. To ensure reproducibility of each parameter the measurement of lung
volumes was repeated at least two times for each parameter and the best value was recorded.
FVC% less than or equal to 79% with normal forced expiratory volume in 1s was defined as
restrictive lung disease. Measurements of carbon monoxide diffusing capacity (DLco) were
also performed to measure the integrity of the blood-gas barrier. DLco measurement was con-
sidered valid if the inspiratory volume of the single breath was at least 90% of the vital capacity.
Immunological tests
ANA, anti-ENA with anti-Scl-70 antibodies (antitopoisomerase antibodies), ACA (anticentro-
mere antibodies), C3 and C4 were measured. ANA antibodies were determined by indirect
immunofluorescence using Hep-2 cells as substrates and autoantibodies specificities were fur-
ther assessed by ELISA (Shield, Dundee, UK).
Echocardiography
Two-dimensional echocardiography Doppler examination was performed and left ventricular
ejection fraction was measured on apical four- and two-chamber views using the Simpson
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method. Pulmonary artery systolic pressure (PASP) was estimated using the tricuspid regurgi-
tation velocity and the Bernoulli equation. Mean PASP on echocardiography in our cohort
was 28.6±6.4 mmHg and 8 patients (25.8%) presented a PASP�35 mmHg. Considering the
importance of increased PASP on echocardiography in patients with scleroderma, we decided
to evaluate all patients with DETECT algorithm. According to STEP 2 of DETECT algorithm
(total risk points >35) five patients underwent right heart catheterization. In none of these five
patients a diagnosis of pulmonary arterial hypertension was confirmed on right heart catheter-
ization, despite a PASP�35 mmHg on echocardiography.
CT scan technique and image analysis
Chest CT scan was performed with a Philips Brilliance-64 scanner (Philips Medical Systems)
periodically calibrated. Acquisition parameters were set to 120 kVp, 212 mAs, 0.5s rotation
time, pitch 1.0. The raw data were processed to create two sets of 1mm thick axial slices, one
using standard reconstruction algorithm (Convolution Kernel D-Philips Medical) and one
using a high-resolution reconstruction algorithm (Convolution Kernel B-Philips Medical).
QA (quantitative analysis) was performed in the set of images with standard reconstruction
algorithm by using Imbio LTA (based on the algorithm of CALIPER—Computer Aided Lung
Informatics for Pathology Evaluation and Rating), a computational platform for the near-real-
time characterization and quantification of lung parenchymal patterns on CT scans [10, 15].
Lung parenchymal patterns include Normal, Hyperlucent, Ground-glass (GG), Reticular, and
Honeycombing. Imbio LTA provided the total lung volume, relative volumes, and absolute
volumes of lung patterns, and their regional distribution within three different lung zones
(upper, middle, lower) in each lung. These data were provided in the output images, in a quan-
titative table, and in a glyph with color-coded sectors whose size is proportional to the percent-
age distribution of that pattern in each lung zone. The relative volumes of GG and Reticular
patterns were added to represent the total burden of disease. The platform provided a fast out-
put of DICOM series as well as a pdf file in which each lung pattern was colored differently,
allowing the evaluation of disease extent, composition, and location at a glance. Moreover, the
final report permitted an easy comparison between baseline and follow-up. Each QA was per-
formed automatically in up to 20’.
SemiQA (semiquantitative analysis) was performed on the images reconstructed with high-
resolution kernel by two chest radiologists (MO, ARL), at first independently from each other
and then after 3 months in consensus. To score the interstitial parenchymal disease we used
the international Goh score at 5 lung levels: 1) origin of great vessels; 2) main carina; 3) pulmo-
nary venous confluence; 4) halfway between the third and fifth section; 5) immediately above
the right hemi-diaphragm [4, 5]. The CT variables scored were total disease extent, extent of
GG pattern, extent of reticular pattern, and coarseness of reticulation. Images were analyzed at
lung window setting. Each semiQA was performed by the radiologists independently in 3 to 5’
whereas in consensus reading in 5 to 10’. In consensus reading the two radiologists assigned a
severity grade to traction bronchiectasis, according to the score reported in literature used for
assessment of idiopathic pulmonary fibrosis [16]. The score took into account the average
degree of airway dilatation within areas of fibrosis as well as the extent of dilatation within the
lobe, with a final score of: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
The widest short-axis diameter of the main pulmonary artery (PA) on axial sections at the
level of PA bifurcation and the widest short-axis diameter of the ascending aorta (Ao) at the
same level of PA measurement were computed with electronic calipers and their ratio (PA/
Ao) was calculated. Mediastinal window setting was used to measure vascular CT parameters.
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A cut-off of 29 mm was used to define pulmonary hypertension on CT, according to the litera-
ture data that report a specificity of 89% and a sensitivity of 87% for this cutoff [17, 18].
Changes in functional parameters and CT scores during follow-up
Clinically disease progression was defined as FVC and DLco composite, consisting of either a
relative FVC decline from baseline >10% or an FVC decline of 5–9% in association with a
DLco decline of>15% [3, 19, 20]. An improvement was defined either an FVC increase from
baseline >10% or an FVC increase of 5–9% in association with a DLco improvement of
>15%. All other outcomes were defined as stability.
Radiologically at QA four different cutoffs were explored (2%, 5%, 10%, 20% [5, 21]) to
define a change from baseline. Progression of disease was defined if the reduction in %Normal
pattern was greater than the cutoff value, improvement if an increase in %Normal pattern
greater than the cutoff value was observed, and stability if none of the above conditions
applied.
Data analysis
Mean and standard deviation (SD) were used to describe quantitative variables. Absolute and
relative frequencies were used to describe qualitative variables.
Intraclass correlation coefficient (ICC) was calculated to compare the concordance between
semiQA scores of independent readers and between semiQA scores obtained by consensus
reading and QA scores [22].
Pearson r correlation coefficient was used to compare QA scores and semiQA scores with
PFT, DLco%, PASP, traction bronchiectases score, and vascular CT parameters, as well as to
compare the variations of FVC% and DLco% between baseline and follow-up (ΔFVC and
ΔDLco).
T-test was used to assess differences in LTA patterns between patients with a PA diameter
�29mm or<29mm [23].
Paired t-test was used to compare means of lung parameters assessed by QA at both base-
line and follow-up.
Cohen k coefficient was used to assess the concordance between functional and radiological
treatment responses using the above-mentioned cutoffs.
Analysis of ROC curves and the corresponding areas under the curve (AUC) were per-
formed to assess the predictability of FVC% and DLco% decline (as detailed above) from varia-
tions in QA patterns (Δ%Normal, Δ%GG, Δ%Reticular, Δ%GG+%Reticular). An AUC value
greater than 0.70 was deemed indicative for accuracy.
A p value <0.05 was deemed statistically significant and data analysis was performed by
using IBM SPSS Statistics 22.
Results
Patients included 27 women (77.1%) and 8 men (22.9%), aged 51.8±11 years. A total of 70 CT
scans were analyzed, 35 at each time point. QA failed in 4/70 scans (6%) due to technical rea-
sons, “field of view too small” in one case and “airways larger than expected size” in three
cases. The final population included 31 patients (aged 51.3±12.1 years; women: 52.6±11.9,
men: 45.5±12.1) with complete clinical and imaging evaluations at both baseline and follow-
up. Because of progression of skin and/or lung involvement 12/31 (38.7%) patients received
treatment with rituximab and 19/31 (61.3%) patients received conventional immunosuppres-
sive drugs. Most patients had diffuse disease (23/31, 74.2%) and were positive for anti-Scl-70
antibodies (26/31, 83.9%). Table 1 reports clinical, functional and imaging data.
A longitudinal quantitative CT analysis of pulmonary parenchyma and vessels in systemic sclerosis
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SSc-ILD lung patterns and their regional distribution
GG was the dominant pattern at both QA and semiQA (18.3% and 22.9%, respectively—
Table 1), whereas honeycombing was absent in this population. At semiQA both %GG and %
Reticular extent grew from apex to base, along with coarseness of reticulation (Table 2). Simi-
larly, QA showed a predilection for lower lung zones for both GG and Reticular patterns, with
an apex-to-base crescendo of alterations (Table 3).
Table 1. Clinical and radiological characteristics at baseline of the 31 patients with SS-ILD.
Age, mean ±SD, yy 51.3±12.1
Disease duration, mean ±SD, yy 8.9±4.8
M/ F, n (%) 6/25 (19.4/80.6)
Early disease/Long disease, n (%) 4/27 (12.9/87.1)
Diffuse/limited skin involvement, n (%) 23/8 (74.2/25.8)
Follow-up, mean ±SD, months 26.0±12.6
Anti-topoisomerase I/ACA/ANA� antibodies, n (%) 26/0/5 (83.9/0.0/16.1)
FVC%, mean ±SD 82.5±22.2
TLC%, mean ±SD 77.0±19.6
RV%, mean ±SD 73.5±21.2
DLco%, mean ±SD 48.4±19.9
Kco, mean ±SD 59.0±21.1
FVC�79%, n (%) 13 (41.9)
FVC�60%, n (%) 5 (16.1)
PASP, mean ±SD, mmHg 28.6±6.4
PASP�35 mmHg, n (%) 8 (25.8)
Vascular parameters PA diameter 26.2 (±2.6)
Ao diameter 30.1 (±3.7)
PA/Ao ratio 0.9 (±0.1)
SemiQA (consensus reading) %Disease Extent 31.4 (±18.9)
%GG 22.9 (±13.3)
%Reticular 8.4 (±7.8)
Coarseness reticulation 4.4 (±2.4)
Traction bronchiectasis score 9.54 (±1.1)






Lung volume (L) 3.8 (±0.8)
Data are reported as mean ± standard deviation. Percentages express the relative volume of each pattern to the whole
lung.
ACA = anti-centromere antibodies, ANA = anti-nuclear antibodies, Ao = ascending aorta, DLco = diffusing lung
capacity for carbon monoxide, F = female, FVC = forced vital capacity, GG = ground-glass, Kco = carbon monoxide
transfer coefficient, L = liters, PA = pulmonary artery, LTA = lung texture analysis, M = male, PASP = pulmonary
artery systolic pressure, QA = quantitative analysis, RV = residual volume, SD = standard deviation,
semiQA = semiquantitative analysis, TLC = total lung volume.
�ANA positivity without specificities.
https://doi.org/10.1371/journal.pone.0213444.t001
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Concordance of QA and semiQA scores
By analyzing all CT scans, QA scores compared to semiQA scores obtained by consensus read-
ing had weak concordance for Reticular pattern (ICC:0.275, 95%CI: 0.029 to 0.489, p = 0.015),
moderate concordance for GG pattern (ICC:0.667, 95%CI: 0.502 to 0.785, p<0.001) and good
concordance for total disease extent (ICC:0.766, 95%CI: 0.640 to 0.852, p<0.001).
SemiQA scores between independent readers had fair concordance for GG pattern
(ICC:0.549, 95%CI: 0.291 to 0.721, p<0.001) and good concordance for total disease extent
(ICC:0.761, 95%CI: 0.572 to 0.863, p<0.001) as well as for Reticular pattern (ICC:0.881, 95%
CI: 0.810 to 0.927, p<0.001).
Imaging scores and pulmonary function
A negative correlation was found between PFT and semiQA scores (r = -0.3 to -0.4, p<0.001)
(Table 4). The correlations were stronger between PFT and QA scores (r = -0.3 to -0.74,
p<0.001) (Table 4). The strongest correlations were between %GG or %GG+Reticular and
TLC% (r = -0.74 and -0.72, respectively) and between %GG or %GG+Reticular and FVC%
(both r = -0.71).
Traction bronchiectases
Traction bronchiectases were present in 25/31 (81%) patients and 50/62 scans, with a severity
score at baseline of 9.54, worsening to 10.8 at follow-up. Traction bronchiectases score signifi-
cantly correlated with QA and semiQA scores, as detailed in Table 4. In particular, Traction
bronchiectases score inversely correlated with %Normal and positively correlated with %GG
and %Reticular at both QA and semiQA. Traction bronchiectases score correlated with DLco
(r = -0.34, p< .01), TLC(r = -0.30, p = .02), and PA diameter (r = 0.34, p< .01), but not with
PASP (r = 0.05, p = .98).
Table 2. Regional distribution of lung patterns at semiQA as performed by consensus reading in each lung level at both baseline and follow-up.
Global score p Level 1 p Level 2 p Level 3 p Level 4 p Level 5 p






.16 32.7 ±22.9 .63 41.9 ±28.1 .72 53.4
±28.1
.70












.23 16.8 ±14.5 .20 32.6
±22.8













.11 13.5 ±15.6 .21 18.4 ±20.2 .70 23.9
±22.5
.12































Values for each lung level (levels are described in the main text) are expressed as means ± standard deviation. p values refers to differences between baseline and follow-
up calculated by using paired t-test.
GG = ground-glass.
https://doi.org/10.1371/journal.pone.0213444.t002
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Vascular analysis
Among vascular parameters (PA diameter, Ao diameter, PA/Ao ratio, PASP) PA diameter was
significantly correlated with both QA and semiQA scores (Table 4). No significant correlations
were found between QA scores and Ao diameter, PA/Ao ratio, PASP. A PA diameter�29mm
distinguished patients with higher QA scores in %GG, %Reticular, %GG+Reticular (p<0.001)
(Table 5), while the value of echocardiographic PASP did not (p>0.05). Those patients with a
PA diameter greater than or equal to 29mm had %GG+Reticular greater than 39% (p<0.001)
and lower lung volumes (p = 0.003) than patients with a PA diameter less than 29mm.
Follow-up evaluation and outcome prediction
Patients were followed-up for 26 (±13) months. At follow-up semiQA and QA showed a predi-
lection of GG and Reticular patterns for lower lung zones, with an apex-to-base crescendo of
alterations (Tables 2 and 3). Between baseline and follow-up no significant differences in pat-
tern extent across the lung zones were observed at QA (Table 3), whereas at semiQA the global
score of %Reticular pattern significantly increased (p = .04, Table 2). Differences in total lung
volume were not significant either (3.83±0.77L at baseline vs 3.75±0.79L at follow-up,
p = 0.345). Among the 25 patients who had traction bronchiectases, in 17 patients the traction
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Values for each lung zone (upper, middle, lower) and are expressed as means ± standard deviation. p values refers to differences between baseline and follow-up
calculated by using paired t-test. Percentages express the relative volume of each pattern to the whole lung.
GG = ground-glass; HC = honeycombing; HyperL = hyperlucent; LL = left lower zone; LM = left middle zone; LU = left upper zone; RL = right lower zone; RM = right
middle zone; RU = right upper zone.
https://doi.org/10.1371/journal.pone.0213444.t003
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bronchiectasis score was stable between baseline and follow-up, whereas in 8 patients the score
upgraded.
ΔFVC had a weak positive correlation with ΔDLco (r = 0.40, p = 0.025).
Table 6 shows the results of clinical and radiological modification during follow-up after
therapy related to different cutoffs (2%, 5%, 10%, 20%) of changes in %Normal at QA, with
Table 4. Pearson’s r correlation coefficients between semi-quantitative (SemiQA) and quantitative (QA) scores with pulmonary function, arterial measurements,
and traction bronchiectasis score.
SemiQA scores QA scores
%Disease Extent %GG %Reticular Coarseness reticulation %Normal %GG %Reticular %GG+%Reticular Lung Volume
FVC% r -0.455 -0.369 -0.484 -0.454 0.698 -0.719 -0.380 -0.709 0.637
p < .001 .003 < .001 < .001 < .001 < .001 .003 < .001 < .001
TLC% r -0.522 -0.447 -0.518 -0.470 0.712 -0.736 -0.427 -0.721 0.748
p < .001 .001 .001 < .001 < .001 < .001 .001 < .001 < .001
RV% r -0.481 -0.438 -0.458 -0.331 0.579 -0.573 -0.533 -0.578 0.606
p .001 .003 .002 .026 < .001 < .001 < .001 < .001 < .001
DLco% r -0.360 -0.272 -0.419 -0.357 0.414 -0.404 -0.301 -0.416 0.268
p .004 .034 .001 .005 .001 .001 .018 .001 .037
Kco r -0.395 -0.290 -0.489 -0.297 0.295 -0.301 -0.192 -0.296 -0.145
p .003 .035 < .001 .031 .032 .028 .169 .032 .299
PA diam. r 0.372 0.312 0.377 0.096 -0.363 0.382 0.263 0.387 -0.256
p .003 .014 .003 .457 .004 .002 .039 .002 .045
Ao diam. r 0.066 0.056 0.066 -0.056 -0.155 0.125 0.180 0.144 0.015
p .620 .673 .621 .674 .242 .346 .172 .275 .908
PA/Ao r 0.258 0.215 0.264 0.097 -0.148 0.198 0.025 0.178 -0.228
p .051 .105 .045 .471 .269 .135 .853 .182 .085
PASP r 0.301 0.329 0.139 -0.346 -0.229 0.192 0.325 0.242 -0.056
p .079 .053 .428 .042 .186 .268 .057 .162 .750
TB score r 0.57 0.44 0.64 0.30 -0.39 0.39 0.25 0.40 -0.06
p < .001 < .001 < .001 .031 .001 .001 .04 .001 .65
Statistically significant correlation coefficients (p<0.05) are in italics, whereas the strongest correlations are in bold.
Ao = ascending aorta, DLco = diffusing lung capacity for carbon monoxide, FVC = forced vital capacity, GG = ground-glass, Kco = transfer coefficient, PA = pulmonary
artery trunk diameter, PA/Ao = pulmonary artery trunk to ascending aorta ratio, PASP = pulmonary artery systolic pressure, RV = residual volume, TB = traction
bronchiectasis, TLC = total lung capacity.
https://doi.org/10.1371/journal.pone.0213444.t004
Table 5. Differences in quantitative analysis (QA) patterns of SSc-ILD according to pulmonary artery diameter.
QA Parameter PA �29mm PA <29mm p
%Normal 60.8 ± 19.5 81.4 ± 16.9 <0.001
%GG 32.6 ± 16.5 14.3 ± 15.2 <0.001
%Hyperlucent 0.1 ± 0.2 0.5 ± 1.6 0.346
%GG+Reticular 38.9 ± 19.5 18.0 ± 17.1 <0.001
%Reticular 6.2 ± 3.9 3.6 ± 3.8 0.022
%Honeycombing 0.1 ± 0.2 0 ± 0 0.090
Lung volume 3.3 ± 0.6 3.9 ± 0.8 0.003
Data are reported as mean ± standard deviation.
GG = ground glass, PA = pulmonary artery, QA = quantitative analysis.
https://doi.org/10.1371/journal.pone.0213444.t005
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cases of improvement (Fig 1), stability and progression (Fig 2). The definition of significant
clinical modification by composite endpoint with FVC and DLco did not correlate with the
radiological score by QA for all the different cutoff values tested: at 2% κ = -0.020, p = 0.853; at
5% κ = -0.016, p = 0.885; at 10% κ = 0.040, p = 0.618; at 20% κ = 0.046, p = 0.232. By increasing
the cutoff of change in %Normal (i.e. from 2% to 20%) the improvement rate declined with a
parallel increase in the progression rate.
Variations in QA patterns between baseline and follow-up (Δ%Normal, Δ%GG, Δ%Reticu-
lar, Δ%GG+Reticular) were not accurate (AUC:0.50 to 0.70; p>0.05) in predicting disease pro-
gression as assessed by PFT. However, variation in total lung volume calculated by Imbio LTA
accurately predicted the composite functional respiratory endpoint with FVC% and DLco%
(AUC = 0.74; 95%CI: 0.54 to 0.93; p = 0.03) (Table 7) (Fig 3). A reduction in total lung volume
greater than 7.18% predicted a progression of disease as of a combined decline in FVC% and
DLco% with a sensitivity of 81% and a specificity of 70%. Conversely, Imbio LTA did not accu-
rately predict changes in FVC% and DLco% alone (Table 7).
Discussion
Our study provides evidence that QA can detect and objectively quantify SSc-ILD modifica-
tion at CT during treatment and that QA has a weak-to-good concordance with semiQA per-
formed by thoracic radiologists. Moreover, QA correlates better than semiQA with functional
data, and both scores correlate with PA diameter at CT. Finally, our results show that changes
in lung volumes measured by QA and not changes in QA patterns were able to predict changes
in the composite functional respiratory endpoint with FVC% and DLco% and that clinical and
quantitative radiological definitions of disease modification during treatment have a weak
correlation.
QA revealed that GG and Reticular patterns characterized the SSc-ILD in all cases, with an
apex-to-base crescendo of alterations for both patterns, in line with a previous study [4].
SemiQA had a good inter-reader concordance for evaluating the total disease extent and the
Reticular pattern, and only fair for the GG pattern. The inter-reader concordance for total dis-
ease extent in our study was better than that reported by Moore et al. [24], likely because the
reading of CT scans was performed by two dedicated chest radiologists in our study. Nonethe-
less, the inter-reader concordance for GG pattern was likely affected by the gradual contiguity
or frank superimposition with Reticular pattern, as observed in most cases. This issue persists
Table 6. Clinical and radiological modifications in response to therapy according to groups of therapy (either rituximab or other conventional immunosuppressive
drugs) and to different cut-offs (2%, 5%, 10%, 20%) of changes in %Normal at QA.
Therapy Improvement Stability Progression
Composite functional endpoint FVC+DLco RTX 4/12 (33.3%) 6/12 (50%) 2/12 (16.7%)
Others 6/19 (31.6%) 4/19 (21%) 9/19 (47.4%)
QA Δ%Normal>2% RTX 6/12 (50%) 0 6/12 (50%)
Others 7/19 (36.8%) 0 12/19 (63.2%)
QA Δ%Normal>5% RTX 5/12 (41.7%) 0 7/12 (58.3%)
Others 5/19 (26.3%) 1/19 (5.3%) 13/19 (68.4%)
QA Δ%Normal>10% RTX 3/12 (25%) 2/12 (16.7%) 7/12 (58.3%)
Others 2/19 (10.5%) 4/19 (21%) 13/19 (68.4%)
QA Δ%Normal>20% RTX 1/12 (8.3%) 0 11/12 (91.7%)
Others 0 0 19/19 (100%)
DLco = diffusing capacity for carbon monoxide, FVC = forced vital capacity, QA = quantitative analysis, RTX = rituximab.
https://doi.org/10.1371/journal.pone.0213444.t006
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also with QA, as these regions represent mixed or transitional microscopic involvement [25].
However, QA defines each voxel as either GG or Reticular. This may lead semiQA to overesti-
mate the superimposition between the two patterns and could in part explain not only the fair
inter-reader concordance for GG pattern at semiQA, but also the weak concordance for Retic-
ular pattern between semiQA and QA scores. This weak concordance was also observed con-
sidering the changes in Reticular pattern between baseline and follow-up. Indeed, we found no
significant difference in %Reticular pattern at QA versus a slight difference in %Reticular pat-
tern at semiQA as of global score and not evident at each lung level. Another possible cause of
low concordance between semiQA and QA scores can be the different methodology, as QA is
based on a 3D analysis of the entire lungs whereas semiQA is based on a 2D analysis per-
formed at five predefined levels.
These methodological differences could in part justify the stronger correlation between
PFT and QA in comparison to semiQA. In particular, in our study the strongest correlations
were seen between %GG or %GG+Reticular and TLC% (r = -0.74 and -0.72, respectively) and
between %GG or %GG+Reticular and FVC% (both r = -0.71). Our results showed overall
Fig 1. 44 years-old woman showing an improvement of ILD at QA after therapy with rituximab. PFT revealed an increase in FVC% (87% to 101%) and a
decrease in DLco% (69% to 50%). Axial chest CT scans at the same level at baseline (A) and follow-up (B) show reduction of the diffuse and bilateral ground-
glass opacities with a complete disappearance of the superimposed subpleural reticulation in the lower lobes. QA analysis performed by Imbio LTA shows an
increase in total lung volumes (3.8L to 4.6L) and in %Normal pattern (74% to 97%) with a reduction in %GG (20% to 1%) and %Reticular (6% to 2%) patterns,
as shown in the glyphs (C).
https://doi.org/10.1371/journal.pone.0213444.g001
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Fig 2. 46 years-old woman showing a progression of ILD at QA after therapy with rituximab. PFT revealed a mild increase in FVC% (90% to 97%) and a
stability in DLco% (27%). Axial chest CT scans at the same level at baseline (A) and follow-up (B) show increase of the diffuse and bilateral ground-glass
opacities more evident in the subpleural regions in both lower lobes associated with fine intralobular reticulation. QA analysis performed by Imbio LTA shows
a reduction in total lung volumes (4.4L to 3.9L) and in %Normal pattern (83% to 61%) with an increase in %GG (15% to 35%) and %Reticular (2% to 4%)
patterns, as summarized in the glyphs (C).
https://doi.org/10.1371/journal.pone.0213444.g002
Table 7. ROC curves and associated AUC relative to progression of SSc-ILD.
Δ Δ FVC + DLco FVC <79% at follow-up Δ FVC% Δ DLco%
AUC p AUC p AUC p AUC p
%Normal 0.51 (0.29–0.74) .89 0.59 (0.38–0.81) .372 0.43 (0.18–0.68) .629 0.47 (0.22–0.71) .777
%GG 0.54 (0.29–0.79) .726 0.66 (0.44–0.88) .165 0.57 (0.28–0.86) .626 0.45 (0.17–0.72) .677
%Reticular 0.70 (0.51–0.89) .078 0.62 (0.42–0.82) .262 0.70 (0.53–0.88) .156 0.63 (0.41–0.85) .258
%GG+Reticular 0.52 (0.30–0.75) .826 0.61 (0.40–0.81) .318 0.54 (0.29–0.80) .760 0.51 (0.25–0.76) .946
Lung Volume 0.74 (0.54–0.93) .035 0.74 (0.57–0.92) .021 0.33 (0.10–0.56) .237 0.40 (0.15–0.66) .408
Values in parenthesis are 95%CI. ROC curves were calculated to assess the predictability of FVC% and DLco% decline from variations in QA patterns (Δ%Normal, Δ%
GG, Δ%Reticular, Δ%GG+%Reticular). Progression was defined clinically as a FVC and DLco composite endpoint, consisting of either an FVC decline from baseline
>10% or an FVC decline of 5–9% in association with a DLco decline of >15%. ROC curve of the composite functional endpoint is shown in Fig 3. Statistically
significant p values (p<0.05) are in bold.
https://doi.org/10.1371/journal.pone.0213444.t007
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better correlations between PFT and LTA than those reported in previous studies (r = -0.64 for
FVC%) [10, 16]. The correlations between DLco% and the lung patterns of disease at both QA
and semiQA were statistically significant, but low (r = -0.27 to -0.42) and slightly lower than
that reported in a previous study on IPF patients analyzed by the same algorithm (r = -0.56)
[16]. These correlations could mirror the combined vascular and inflammatory/fibrotic
changes peculiar of scleroderma pathogenesis and may improve in next future with the seg-
mentation of pulmonary vessels by dedicated software, especially if able to separate arteries
from veins [26, 27].
The role of vascular impairment and endothelial dysfunction in SSc is fundamental in the
pathogenesis of the disease [1]. The good correlations observed between SSc-ILD extent and
PA diameter may reflect cor pulmonale from hypoxaemia (as seen in chronic obstructive pul-
monary disease and obstructive sleep apnea), but may also support the hypothesis of vascular
impairment associated to lung parenchymal changes of SSc-ILD. However, the pathophysio-
logical mechanism underlying this relationship requires further investigation. A possible
hypothesis could be the presence of a reduced vascular volume in fibrotic areas coupled by a
thickening of the vessel intima in the spared areas, similarly to what has been speculated in IPF
patients [28]. The involvement of pulmonary vessels elevates PA pressure and this is reflected
on such a simple measurement as PA diameter. In a recent study the PA diameter revealed to
Fig 3. ROC curve of lung volume at QA to predict the FVC and DLco composite end-point. The variation in total
lung volume calculated by Imbio LTA accurately predicted the composite functional respiratory endpoint with FVC%
and DLco% (AUC = 0.74; 95%CI: 0.54 to 0.93; p = 0.03), but not changes in FVC% and DLco% alone (see also
Table 6).
https://doi.org/10.1371/journal.pone.0213444.g003
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be a good predictor of pulmonary hypertension (AUC of 0.88) in patients with SSc-ILD, even
better than lung density measured as Perc85 [24]. A number of studies regarding the diagnos-
tic potential of PA diameter as well as PA/Ao ratio have been extensively studied, using differ-
ent cutoffs ranging from 25mm to 33mm. However, a recent meta-analysis on CT pulmonary
artery measurements for the detection of pulmonary arterial hypertension showed that PA
diameter measurement had 79% sensitivity and 83% specificity in diagnosing pulmonary
hypertension, with a good overall accuracy, even better than echocardiography [23]. Further-
more, the meta-analysis revealed that PA diameter has better discriminatory ability than PA/
Ao ratio in assessing pulmonary arterial hypertension [23], being in line with our results.
The strong correlation between PA diameter measurements and QA scores demonstrated
in our study could help in distinguishing those patients with a more severe prognosis also
when QA cannot be performed and it could further reveal the increase of PA pressure earlier
than echocardiography [23].
PA diameter correlated also with traction bronchiectases, a radiological indirect sign of
fibrosis. Traction bronchiectases are receiving growing attention in the medical community
for their potential role in differentiating fibrotic and inflammatory ground-glass in ILD.
Although the traction bronchiectases score is subjective, likewise any semiQA analysis, it has
been demonstrated that determining the presence or absence of traction bronchiectases has a
higher level of observer agreement than honeycombing [29]. The evaluation of traction bron-
chiectases is still demanded only to radiologst’ eye, as no accurate quantitative imaging tool is
available nowadays to identify them and distinguish them from honeycombing, hyperlucent
areas, or cysts.
This is the first study to evaluate QA performed by using Imbio LTA in patients with SSc-
ILD during treatment follow-up. Changes in %Normal pattern were not accurate in predicting
disease progression as defined by PFT. However, variation in lung volume calculated by LTA
accurately predicted the composite functional respiratory endpoint with FVC% and DLco%
(AUC of 0.74), which is the only accepted endpoint in SSc-ILD. It follows that functional data
reflect lung volumes, but not disease extent and pattern type as radiologically quantified.
While the clinical relevance of serial changes on CT is yet to be established, this clinical-radio-
logical dissociation could improve the accuracy in objectively identifying CT serial changes in
total disease extent as well as in different patterns, earlier than functional changes. In a previ-
ous study Moore et al. showed that a substantial deterioration in PFT (>30%) is needed to
detect a major change at CT scoring performed by semiQA [30]. The advent of new expensive
biological therapies for SSc created the need for an accurate evaluation of disease extent, pat-
tern, and progression by using objective and reproducible tools. Imbio LTA performs a volu-
metric evaluation of parenchymal changes, showing modifications in lung patterns not
revealed by PFT. The results of most important clinical trials on SSc-ILD are mainly based on
PFT changes, demonstrating a limited although significant effect on FVC and DLco. Func-
tional modifications during treatment are mandatory in evaluating these patients to assess
patient prognosis [3]. However, the use of functional parameters as surrogate markers of dis-
ease progression has important limitations (i.e. significant intra-individual variability [31, 32],
indirect estimation of fibrosis, the lack of evaluation of coexistent emphysema and/or pulmo-
nary hypertension [33–35]). The position paper of the Fleischner Society on ILD recom-
mended to investigate serial CT scans as part of a composite endpoint with trends in PFT and
pointed at the multidisciplinary integration of CT with serial PFT as an area of future research
[36]. Our study supports this perspective, with the suggestion of discussing QA results along
with qualitative CT findings at the multidisciplinary meetings to assess more objectively the
response to therapy and to ultimately personalize patient therapy. Indeed, QA provides consis-
tent results that could be monitored and quantified, including not only an overall
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quantification of lung involvement, but also a precise definition of the lung patterns of disease
[37]. Severity of traction bronchiectasis and increasing extent of honeycombing, unlike GG,
have been reported as the strongest determinants of mortality in connective tissue diseases
related ILD [29]. The recognition of the different patterns, including GG, as well as of the sub-
tle changes by QA could be useful in targeting patient therapy and in assessing treatment effi-
cacy, as recently suggested for IPF [37]. Diversification in treatment according to lung patterns
could eventually result into a different prognosis, but nowadays this is just speculative.
The main limitation of this study is the relatively small cohort of subjects included to be
considered representative of the whole SSc population. This aspect could have an impact on
the power of our study. However, patients included were well characterized from both clinical
and imaging perspectives with PFT, echocardiography, semiQA and QA. Furthermore, the
pooling of CT data from one single center has the advantage to reduce the potential misinter-
pretation of QA derived from images obtained in different centers with different CT scanners
and CT protocols. A second limitation regards semiQA, as it was performed by dedicated tho-
racic radiologists, who worked together at the same institution. This could have twisted the
results towards a better inter-reader agreement, while in daily clinical practice general radiolo-
gists may have lower inter-reader concordance. A third limitation regards QA, which failed in
a few cases (4/70 scans) despite observing all the technical parameters needed to perform QA.
The fast technological advances may soon overcome this limitation, presenting already with a
low rate.
Conclusions
QA of lung parenchyma on chest CT scans can objectively quantify specific patterns of ILD
changes during treatment in patients with SSc-ILD. Changes in QA patterns cannot predict
disease progression as defined by functional changes, which only reflect lung volumes and not
disease extent and pattern type. A single consistent measurement of PA diameter at CT reflects
the interstitial involvement in patients with SSc, distinguishing patients with a more severe
prognosis. Our results express the need of further investigation on this topic in both basic and
clinical research. Basic research on pulmonary vessels in patients with SSc-ILD may deepen
our knowledge on the endothelial dysfunction in SSc, whereas clinical research could benefit
from the use of objective imaging biomarkers as endpoints to eventually treat patients with a
more personalized approach.
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